Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa ...
The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...
Processa Pharmaceuticals (PCSA) reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
TipRanks on MSN
Eli Lilly’s phase 2 study on imlunestrant: A potential game-changer in breast cancer treatment
Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a Phase 2 ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The treatment consisted of two cycles of immunotherapy before ...
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...
Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback